A New Pathophysiological Aspect of S100B in Schizophrenia: Potential Regulation of S100B by Its Scavenger Soluble RAGE

Biological Psychiatry

Volumn 65, Issue 12, 2009, Pages 1107-1110

  Steiner, Johann ^a   Walter, Martin ^a   Wunderlich, Michael T ^a   Bernstein, Hans Gert ^a   Panteli, Benjamin ^a   Brauner, Mareike ^a   Jacobs, Roland ^b   Gos, Tomasz ^a,c   Rothermundt, Matthias ^d   Bogerts, Bernhard ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

S 100B; S100 beta; S100B; schizophrenia; soluble RAGE; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PROTEIN S100B;

ACUTE DISEASE; ADULT; ARTICLE; CARBOHYDRATE ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DISEASE COURSE; FEMALE; HUMAN; MALE; PARANOID SCHIZOPHRENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DETERMINATION; PSYCHOPATHY; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOASSAY; MALE; NERVE GROWTH FACTORS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS; SCHIZOPHRENIA, PARANOID;

EID: 67349266228     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.10.044     Document Type: Article

References (20)

1. Steiner J., Bernstein H.G., Bogerts B., Gos T., Richter-Landsberg C., Wunderlich M.T., et al. S100B is expressed in, and released from, OLN-93 oligodendrocytes: Influence of serum and glucose deprivation. Neuroscience 154 (2008) 496-503
2. Whitaker-Azmitia P.M., Wingate M., Borella A., Gerlai R., Roder J., and Azmitia E.C. Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: Implications for Alzheimer's disease and Down's syndrome. Brain Res 776 (1997) 51-60
3. Liu J., Shi Y., Tang J., Guo T., Li X., Yang Y., et al. SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem Biophys Res Commun 328 (2005) 335-341
4. Selemon L.D., Mrzljak J., Kleinman J.E., Herman M.M., and Goldman-Rakic P.S. Regional specificity in the neuropathologic substrates of schizophrenia: A morphometric analysis of Broca's area 44 and area 9. Arch Gen Psychiatry 60 (2003) 69-77
5. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE (in press): NSE is unaltered whereas S100B is elevated in serum of patients with schizophrenia-original research and meta-analysis. Psych Res. DOI: 10.1016/j.psychres.2008.01.002.
6. Schroeter ML, Steiner J (in press): Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry. DOI: 10.1038/mp.2008.85.
7. Steiner J., Bielau H., Bernstein H.G., Bogerts B., and Wunderlich M.T. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 77 (2006) 1284-1287
8. Steiner J., Bernstein H.G., Bielau H., Farkas N., Winter J., Dobrowolny H., et al. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: A morphometric study. J Psychiatr Res 42 (2008) 868-876
9. Rothermundt M., Ohrmann P., Abel S., Siegmund A., Pedersen A., Ponath G., et al. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 361-364
10. Donato R. RAGE: A single receptor for several ligands and different cellular responses: The case of certain S100 proteins. Curr Mol Med 7 (2007) 711-724
11. Geroldi D., Falcone C., and Emanuele E. Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Curr Med Chem 13 (2006) 1971-1978
12. Park L., Raman K.G., Lee K.J., Lu Y., Ferran Jr. L.J., Chow W.S., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 (1998) 1025-1031
13. Yan S.S., Wu Z.Y., Zhang H.P., Furtado G., Chen X., Yan S.F., et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 9 (2003) 287-293
14. Norata G.D., Garlaschelli K., Grigore L., Tibolla G., Raselli S., Redaelli L., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. [published online ahead of print June 30]. Nutr Metab Cardiovasc Dis (2008) DOI: 10.1016/j.numecd.2008.03.004
15. Adami C., Bianchi R., Pula G., and Donato R. S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain. Biochim Biophys Acta 1742 (2004) 169-177
16. Bianchi R., Adami C., Giambanco I., and Donato R. S100B binding to RAGE in microglia stimulates COX-2 expression. J Leukoc Biol 81 (2007) 108-118
17. Pullerits R., Bokarewa M., Dahlberg L., and Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 7 (2005) R817-R824
18. Ohtaki N., Kamitani W., Watanabe Y., Hayashi Y., Yanai H., Ikuta K., et al. Downregulation of an astrocyte-derived inflammatory protein, S100B, reduces vascular inflammatory responses in brains persistently infected with Borna disease virus. J Virol 81 (2007) 5940-5948
19. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., and Kouassi E. Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol Psychiatry 63 (2008) 801-808
20. Drzyzga L., Obuchowicz E., Marcinowska A., and Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 20 (2006) 532-545